Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03086421
Other study ID # SEDYC
Secondary ID NCI-2021-05585
Status Active, not recruiting
Phase
First received
Last updated
Start date July 11, 2017
Est. completion date September 2024

Study information

Verified date May 2024
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences. In typically-developing children, it is known that these experiences - and the skills that are learned during them - are critical to later well-being. Very little is known about the psychological functioning of young children with cancer, as studies have predominantly focused on those who are older (at least 8 years of age). This study will explicitly assess social functioning in preschool-aged children with cancer and follow the development of their social functioning from the end of treatment into survivorship. The goals of this pilot study are to begin to assess the impact of missed early childhood social experiences, as well as the interaction with developing neurocognitive problems. PRIMARY OBJECTIVE: Explore the impact of cancer in the central nervous system on social functioning of young children (ages 4-6) after completion of therapy.


Description:

Participants will be evaluated using the same or similar questionnaires at two time points. The first assessment will take place when they are 6-12 months post the end of treatment. Participants and their parents/legal guardian will complete an assessment of social and cognitive functioning by completing questionnaires about social, emotional, behavioral, and executive functioning. If the study participant agrees, they will identify another adult (that is, teacher or daycare employee) who may be contacted to complete questionnaires about the participant's social and behavioral functioning. A follow-up study visit will occur about two years later.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 64
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years to 6 Years
Eligibility Inclusion Criteria: - Primary Diagnosis of a brain or non-CNS solid tumor - Between 4 and 6 years of age at enrollment - Between 6 and 12 months post-therapy at the time of enrollment - Treatment plan included chemotherapy - English speaking - Cognitive and language capacity to complete measures Exclusion Criteria: - Diagnosis of a genetic disorder/pre-existing neurodevelopmental condition associated with neurocognitive or social impairment (e.g., autism, Neurofibromatosis Type 1 (NF1), Down syndrome) - Solid tumor patients who required CNS-directed therapy (e.g., radiation, intrathecal chemotherapy) - Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaires
Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.

Locations

Country Name City State
United States St. Jude Children's Research Hospital Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Social functioning as assessed by parent-completed measures and child-completed measures Descriptive statistics will be provided. Parents will complete the Social Competence Inventory, Quality of Play Questionnaire, and the NIH Toolbox. Patients completed measures include the subtests from the NIH Toolbox, Challenging Situations Task, and Developmental Neuropsychological Assessment (2nd edition). Analyses will be completed to assess performance on these measures at each time point and to assess change over time. Analyses will be completed by diagnostic group (brain tumor versus solid tumor). All measures will be completed at both the study enrollment and 24±3 months later
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1
Recruiting NCT04738162 - Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors Phase 2
Not yet recruiting NCT06093165 - RE-irradiation of Diffuse MIdline Glioma paTients N/A
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Not yet recruiting NCT05553899 - PET-MRI in Paediatric Brain Tumours N/A
Recruiting NCT05709522 - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Recruiting NCT04722237 - Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing N/A
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT04670016 - HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Active, not recruiting NCT03361033 - Components of Social Functioning in Survivors of Pediatric Brain Tumors
Active, not recruiting NCT04525014 - RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors Phase 1
Recruiting NCT05672043 - Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Completed NCT03871686 - Promotion of Well-being of Young Adult Brain Cancer Survivors N/A
Withdrawn NCT04019470 - Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Active, not recruiting NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Phase 1
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1